Patents by Inventor Manmohan Reddy Leleti
Manmohan Reddy Leleti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250145606Abstract: The present disclosure is directed to compounds having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.Type: ApplicationFiled: November 1, 2024Publication date: May 8, 2025Applicant: Arcus Biosciences, Inc.Inventors: Srijita Bhowmik, Karen Yir Jing Chen, Jeremy Fournier, Jenna Leigh Jeffrey, Manjunath Lamani, Manmohan Reddy Leleti, Guillaume Mata, Hyunyoung Moon, Pradeep Nareddy, Srinivas Paladugu, Zhang Wang, Xuelei Yan, Monika Yadav, Jiang Zhu
-
Patent number: 12226425Abstract: Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.Type: GrantFiled: November 15, 2019Date of Patent: February 18, 2025Assignee: Arcus Biosciences, Inc.Inventors: Joel Beatty, Eric Thomas Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Corinne Nicole Foley, Rebecca Louise Grange, Tezcan Guney, Steven Donald Jacob, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Erick Allen Lindsey, Debashis Mandal
-
Patent number: 12195482Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.Type: GrantFiled: August 14, 2024Date of Patent: January 14, 2025Assignee: Arcus Biosciences, Inc.Inventors: Joel Worley Beatty, Corinne Nicole Foley, Balint Gal, Manjunath Lamani, Manmohan Reddy Leleti, Dillon Harding Miles, Srinivas Paladugu, Jay Patrick Powers, Shiwei Qu
-
Patent number: 12195447Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.Type: GrantFiled: October 22, 2021Date of Patent: January 14, 2025Assignee: ARCUS BIOSCIENCES, INC.Inventors: Joel Beatty, Laurent Debien, Jenna Jeffrey, Manmohan Reddy Leleti, Debashis Mandal, Dillon Miles, Jay Powers, Brandon Rosen, Ehesan Sharif, Rhiannon Thomas-Tran
-
Publication number: 20250011318Abstract: Disclosed herein are compounds having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.Type: ApplicationFiled: May 24, 2024Publication date: January 9, 2025Applicant: ARCUS BIOSCIENCES, INC.Inventors: Srikanth Kumar Gangam, Clayton Hardman, Kenneth Victor Lawson, Manmohan Reddy Leleti, Dongdong Liu, Artur Karenovich Mailyan, Masa Podunavac, Shiwei Qu, Zhang Wang, Xianglin Yin, Kai Yu, Tzu-Yu Yu
-
Publication number: 20240425497Abstract: Disclosed herein are compounds that are Cbl-b inhibitors having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.Type: ApplicationFiled: May 3, 2024Publication date: December 26, 2024Applicant: ARCUS BIOSCIENCES, INC.Inventors: Srikanth Kumar Gangam, Clayton Hardman, Kenneth Victor Lawson, Manmohan Reddy Leleti, Dongdong Liu, Artur Karenovich Mailyan, Masa Podunavac, Shiwei Qu, Xianglin Yin, Kai Yu, Tzu-Yu Yu
-
Publication number: 20240425526Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.Type: ApplicationFiled: August 14, 2024Publication date: December 26, 2024Applicant: Arcus Biosciences, Inc.Inventors: Joel Worley Beatty, Corinne Nicole Foley, Balint Gal, Manjunath Lamani, Manmohan Reddy Leleti, Dillon Harding Miles, Srinivas Paladugu, Jay Patrick Powers, Shiwei Qu
-
Patent number: 12168023Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.Type: GrantFiled: April 8, 2024Date of Patent: December 17, 2024Assignee: Arcus Biosciences, Inc.Inventors: Laurent Pierre Paul Debien, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
-
Patent number: 12145901Abstract: The present disclosure describes processes and intermediates useful for preparing a compound of Formula (Xa) or Formula (Xb). The processes and intermediates can be used to prepare the compounds of the disclosure at multigram or kilogram scale.Type: GrantFiled: September 16, 2022Date of Patent: November 19, 2024Assignee: Arcus Biosciences, Inc.Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Fournier, Balint Gal, Karl T. Haelsig, Clayton Hardman, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Artur Karenovich Mailyan, Guillaume Mata, Brandon Reid Rosen, Zhang Wang, Kai Yu
-
Patent number: 12139475Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.Type: GrantFiled: August 1, 2022Date of Patent: November 12, 2024Assignee: CHEMOCENTRYX, INC.Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Manmohan Reddy Leleti, Rebecca M. Lui, Viengkham Malathong, Jay P. Powers, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
-
Publication number: 20240352057Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.Type: ApplicationFiled: November 21, 2023Publication date: October 24, 2024Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ui Sharif
-
Patent number: 12103907Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.Type: GrantFiled: August 30, 2023Date of Patent: October 1, 2024Assignee: Arcus Biosciences, Inc.Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
-
Publication number: 20240299306Abstract: The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.Type: ApplicationFiled: February 9, 2024Publication date: September 12, 2024Inventors: Manmohan Reddy LELETI, Jay P. POWERS
-
Publication number: 20240285665Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.Type: ApplicationFiled: April 8, 2024Publication date: August 29, 2024Inventors: Laurent Pierre Paul DEBIEN, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan UI Sharif
-
Patent number: 12071411Abstract: The present disclosure is directed to compounds that are inhibitors of HIF-2? having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.Type: GrantFiled: October 28, 2022Date of Patent: August 27, 2024Assignee: Arcus Biosciences, Inc.Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Fournier, Balint Gal, Clayton Hardman, Artur Karenovich Mailyan, Kenneth Victor Lawson, Manmohan Reddy Leleti, Dongdong Liu, Guillaume Mata, Ma{hacek over (s)}a Podunavac, Jay Patrick Powers, Brandon Reid Rosen, Kai Yu
-
Patent number: 12064433Abstract: Compound that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.Type: GrantFiled: July 26, 2019Date of Patent: August 20, 2024Assignee: ARCUS BIOSCIENCES, INC.Inventors: Manmohan Reddy Leleti, Debashis Mandal, Dillon Harding Miles, Jay Patrick Powers, Brandon Reid Rosen, Ehesan U I Sharif
-
Publication number: 20240254079Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.Type: ApplicationFiled: August 30, 2023Publication date: August 1, 2024Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy Thomas Andre FOURNIER, Balint GAL, Tezcan GUNEY, Karl T. HAELSIG, Clayton HARDMAN, Steven Donald JACOB, Jenna Leigh JEFFREY, Jaroslaw KALISIAK, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Artur Karenovich MAILYAN, Debashis MANDAL, Guillaume MATA, Hyunyoung MOON, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Zhang WANG, Xuelei YAN, Kai YU
-
Publication number: 20240246967Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by AXL.Type: ApplicationFiled: May 20, 2022Publication date: July 25, 2024Inventors: Corinne Nicole FOLEY, Manjunath LAMANI, Manmohan Reddy LELETI, Dillon Harding MILES, Pradeep NAREDDY, Srinivas PALADUGU, Jay Patrick POWERS, Shiwei QU, Joice THOMAS, Ehesan Ul SHARIF, Rebecca Louise GRANGE, Guiling ZHAO
-
Publication number: 20240226115Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by AXL.Type: ApplicationFiled: May 20, 2022Publication date: July 11, 2024Inventors: Corinne Nicole FOLEY, Manjunath LAMANI, Manmohan Reddy LELETI, Dillon Harding MILES, Srinivas PALADUGU, Jay Patrick POWERS, Shiwei QU, Ehesan Ul SHARIF, Rebecca Louise GRANGE, Guiling ZHAO
-
Patent number: 11993584Abstract: The present invention provides solid forms, solvates and hydrates of 3-[2-amino-6-(1-{[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl}-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl]-2-methylbenzonitrile (Compound I), and methods of making and using the same.Type: GrantFiled: July 17, 2019Date of Patent: May 28, 2024Assignee: ARCUS BIOSCIENCES, INC.Inventors: Jenna Leigh Jeffrey, Manmohan Reddy Leleti, Dillon Harding Miles, Jay Patrick Powers